You are here

Enrollment Completed in Phase 2 Theratope Vaccine Study in Women With Metastatic Breast Cancer

EDMONTON, July 27 /PRNewswire-FirstCall/ -- Biomira Inc. (TSX:BRA) of Edmonton, Alberta, Canada, today announced the completion of enrollment in the Phase II Theratope single-arm study treating women with metastatic breast cancer who are also being treated concurrently with aromatase inhibitors, a type of hormonal therapy, or Faslodex (fulvestrant), an estrogen-receptor antagonist. The trial enrolled 95 women in the United States. Enrolment will remain open until approximately the end of August to allow potential patients now being screened by investigators to be enrolled.

The study's primary objective is to determine the response of the immune system in these women. Additional endpoints are the safety and tolerability of this combination of treatment. Immunology data is expected to be available in 2005. This study may provide useful information relating to the prestratified subset of hormonal therapy plus Theratope-treated patients in our Phase III metastatic breast cancer trial currently under review.

Biomira recently announced that Merck KGaA of Darmstadt, Germany had returned the rights for development and commercialization of Theratope to Biomira. Biomira is currently seeking a new collaborator in order to potentially further develop this product candidate.

Source: Biomira Inc.

Recent Headlines

Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission